Year All202320222021202020192018 May 22, 2023 Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops May 11, 2023 Oculis Co-founders Selected as Finalists in European Inventor Award 2023 April 26, 2023 Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs April 5, 2023 Oculis to Participate at Upcoming Investor Conferences April 4, 2023 Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones March 22, 2023 Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing March 16, 2023 Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial March 9, 2023 Oculis to Present at BioCapital Europe March 3, 2023 Oculis Announces US Public Listing on NASDAQ January 31, 2023 Oculis CEO Riad Sherif MD to Participate in Glaucoma 360 New Horizons Forum
May 22, 2023 Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops
April 26, 2023 Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs
April 4, 2023 Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
March 22, 2023 Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
